BR112012008317A2 - produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal - Google Patents
produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidalInfo
- Publication number
- BR112012008317A2 BR112012008317A2 BR112012008317A BR112012008317A BR112012008317A2 BR 112012008317 A2 BR112012008317 A2 BR 112012008317A2 BR 112012008317 A BR112012008317 A BR 112012008317A BR 112012008317 A BR112012008317 A BR 112012008317A BR 112012008317 A2 BR112012008317 A2 BR 112012008317A2
- Authority
- BR
- Brazil
- Prior art keywords
- steroidal anti
- inflammatory drug
- combination
- sustained release
- amine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
produto de liveração sustentada compreendendo uma combinação de uma amina não-opióide e uma droga anti-inflmatória não-esteroidal. composição farmacêutica oral de liberação sustentada e métodos de utilização, em que as composições são em um forma de dosagem única e incluem um composto contendo amina (incluindo os seus sais), um sal de uma droga anti-inflamatória não-esteróide (aine), e uma matriz hidrofílica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24339109P | 2009-09-17 | 2009-09-17 | |
PCT/US2009/069912 WO2011034554A1 (en) | 2009-09-17 | 2009-12-31 | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012008317A2 true BR112012008317A2 (pt) | 2016-03-22 |
Family
ID=42813081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012008317A BR112012008317A2 (pt) | 2009-09-17 | 2009-12-31 | produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal |
Country Status (7)
Country | Link |
---|---|
US (2) | US9023390B2 (pt) |
EP (1) | EP2477610A1 (pt) |
AU (1) | AU2009352681B2 (pt) |
BR (1) | BR112012008317A2 (pt) |
CA (1) | CA2773521C (pt) |
CL (1) | CL2012000626A1 (pt) |
WO (1) | WO2011034554A1 (pt) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0923836A2 (pt) * | 2008-12-31 | 2015-07-21 | Upsher Smith Lab Inc | Composições farmacêuticas orais contendo opióide e métodos |
EP2477610A1 (en) | 2009-09-17 | 2012-07-25 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
CA2831535C (en) * | 2011-04-07 | 2014-10-21 | Histapharm Inc. | Oral enzyme compositions for intestinal delivery |
BRPI1103205A2 (pt) * | 2011-06-03 | 2014-02-25 | Eurofarma Lab Ltda | Composição farmacêutica oral e uso da composição farmacêutica oral |
US8652527B1 (en) * | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10945973B2 (en) | 2013-11-05 | 2021-03-16 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9700528B2 (en) | 2013-11-05 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9707191B2 (en) | 2013-11-05 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9867819B2 (en) | 2013-11-05 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11213521B2 (en) | 2013-11-05 | 2022-01-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11285146B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10105327B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
US10688066B2 (en) | 2018-03-20 | 2020-06-23 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273134B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
US10933034B2 (en) | 2013-11-05 | 2021-03-02 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291638B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10780064B2 (en) | 2019-01-07 | 2020-09-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11090300B2 (en) | 2013-11-05 | 2021-08-17 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10512643B2 (en) | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US20160324807A1 (en) | 2013-11-05 | 2016-11-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11020389B2 (en) | 2013-11-05 | 2021-06-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11096937B2 (en) | 2013-11-05 | 2021-08-24 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11058648B2 (en) | 2013-11-05 | 2021-07-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9457025B2 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US9861595B2 (en) | 2013-11-05 | 2018-01-09 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10874663B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874664B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9474731B1 (en) | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874665B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11065248B2 (en) | 2013-11-05 | 2021-07-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966974B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966941B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llp | Bupropion as a modulator of drug activity |
US9408815B2 (en) | 2013-11-05 | 2016-08-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123343B2 (en) | 2013-11-05 | 2021-09-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10813924B2 (en) | 2018-03-20 | 2020-10-27 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US10772850B2 (en) | 2013-11-05 | 2020-09-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9457023B1 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10105361B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10980800B2 (en) | 2013-11-05 | 2021-04-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10898453B2 (en) | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US10881657B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US20160361305A1 (en) | 2013-11-05 | 2016-12-15 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US11007189B2 (en) | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966942B2 (en) | 2019-01-07 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10940124B2 (en) | 2019-01-07 | 2021-03-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10786469B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
US10894046B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10799497B2 (en) | 2013-11-05 | 2020-10-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US9763932B2 (en) | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11185515B2 (en) | 2013-11-05 | 2021-11-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9968568B2 (en) | 2013-11-05 | 2018-05-15 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10894047B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10864209B2 (en) | 2013-11-05 | 2020-12-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10080727B2 (en) | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11141416B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10349674B2 (en) | 2017-07-17 | 2019-07-16 | Rai Strategic Holdings, Inc. | No-heat, no-burn smoking article |
WO2019027459A1 (en) * | 2017-08-03 | 2019-02-07 | Sklar Pharma Llc | PROLONGED RELEASE OF NITRIC OXIDE INTO THE INTESTINAL TRACT |
US10925842B2 (en) | 2019-01-07 | 2021-02-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11096419B2 (en) | 2019-01-29 | 2021-08-24 | Rai Strategic Holdings, Inc. | Air pressure sensor for an aerosol delivery device |
US11207711B2 (en) | 2019-08-19 | 2021-12-28 | Rai Strategic Holdings, Inc. | Detachable atomization assembly for aerosol delivery device |
US11889861B2 (en) | 2019-09-23 | 2024-02-06 | Rai Strategic Holdings, Inc. | Arrangement of atomization assemblies for aerosol delivery device |
US11785991B2 (en) | 2019-10-04 | 2023-10-17 | Rai Strategic Holdings, Inc. | Use of infrared temperature detection in an aerosol delivery device |
US11304451B2 (en) | 2019-10-18 | 2022-04-19 | Rai Strategic Holdings, Inc. | Aerosol delivery device with dual reservoir |
US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL58285A (en) | 1978-10-04 | 1983-10-31 | Merck & Co Inc | Pharmaceutical compositions having skeletal muscle relaxant activity,comprising cyclobenzaprine together with diflunisal |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
DE3737154A1 (de) * | 1986-11-03 | 1988-07-28 | Sandoz Ag | Analgetische praeparate |
US6127352A (en) | 1988-02-01 | 2000-10-03 | Uribe; Jose R. | Pharmaceutical compositions with analgesics containing codeine |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5330766A (en) | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
IT1255007B (it) | 1991-07-01 | 1995-10-11 | Altergon Sa | Sale solubile dell'ibuprofen c0n n-(2-idrossietil) pirrolidina e composizioni farmaceutiche che li contengono. |
US5516803A (en) | 1991-10-30 | 1996-05-14 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
AU661723B2 (en) | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US7070806B2 (en) | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
JP3278192B2 (ja) | 1992-04-03 | 2002-04-30 | ロート製薬株式会社 | 徐放性液剤 |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
BE1011045A3 (fr) | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
AU7916798A (en) | 1997-05-22 | 1998-12-11 | Boots Company Plc, The | Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat |
WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
AU5134699A (en) | 1998-07-24 | 2000-02-14 | Andrix Pharmaceuticals, Inc. | Granule modulating hydrogel system |
DK1126826T6 (en) | 1998-11-02 | 2019-06-24 | Alkermes Pharma Ireland Ltd | Multiparticulate modified release of methylphenidate |
EP1204406A2 (en) | 1999-07-29 | 2002-05-15 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
DE19940944B4 (de) | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retardierte, orale, pharmazeutische Darreichungsformen |
ES2226886T3 (es) | 1999-08-31 | 2005-04-01 | Grunenthal Gmbh | Forma de administracion de accion retardada que contiene sacarinato de tramadol. |
DE10023699A1 (de) | 1999-08-31 | 2001-04-19 | Gruenenthal Gmbh | Retardierte Darreichungsform enthaltend Tramadolsaccharinat |
NZ529928A (en) | 1999-10-29 | 2005-10-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
HU229705B1 (en) | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
KR101045144B1 (ko) | 2000-10-30 | 2011-06-30 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
US20040204413A1 (en) | 2001-01-26 | 2004-10-14 | Joaquina Faour | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
ATE493130T1 (de) | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
JP2004534056A (ja) | 2001-06-08 | 2004-11-11 | エンドー ファーマシューティカルズ, インコーポレイティド | アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス |
US6695088B2 (en) | 2001-06-28 | 2004-02-24 | Honda Giken Kogyo Kabushiki Kaisha | Air management system for a motorcycle |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030049317A1 (en) | 2001-08-30 | 2003-03-13 | Lindsay David R. | Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
ES2500117T3 (es) | 2002-02-22 | 2014-09-30 | Shire Llc | Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas |
EP2243471A1 (en) | 2002-04-05 | 2010-10-27 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
AU2003228654A1 (en) | 2002-04-29 | 2003-11-17 | The General Hospital Corporation | Compositions and methods for preventing abuse of orally administered medications |
EP1545468A4 (en) | 2002-09-20 | 2007-06-20 | Alpharma Inc | SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE |
EP1603593A4 (en) | 2002-11-15 | 2007-08-01 | Branded Products For The Futur | PHARMACEUTICAL COMPOSITION |
CA2510465A1 (en) | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
AU2004270188B8 (en) | 2003-09-03 | 2010-04-29 | Mallinckrodt Inc. | Granular sustained release preparation and production thereof |
JP5563731B2 (ja) | 2003-09-26 | 2014-07-30 | アルザ・コーポレーシヨン | オピオイドおよび非オピオイド鎮痛薬の制御放出製剤 |
US20080031901A1 (en) | 2004-09-24 | 2008-02-07 | Abbott Laboratories | Sustained release monoeximic formulations of opioid and nonopioid analgesics |
US20050074493A1 (en) | 2003-10-03 | 2005-04-07 | Mehta Atul M. | Extended release formulations of opioids and method of use thereof |
MXPA06003769A (es) | 2003-11-04 | 2006-07-03 | Shire Lab Inc | Liberacion sostenida de moleculas farmacologicamente activas cargadas positivamente a partir de una matriz que contiene polimeros con atomos de oxigeno polarizados. |
WO2005046663A1 (en) | 2003-11-04 | 2005-05-26 | Shire Laboratories, Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
EP1706098A4 (en) | 2003-11-26 | 2012-08-15 | Supernus Pharmaceuticals Inc | MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
WO2005067889A1 (en) | 2003-12-30 | 2005-07-28 | Durect Corporation | Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
AU2005295482B2 (en) | 2004-10-15 | 2011-03-31 | Supernus Pharmaceuticals Inc. | Less abusable pharmaceutical preparations |
US20060177380A1 (en) | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
WO2007013975A2 (en) | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
US20070042041A1 (en) | 2005-08-17 | 2007-02-22 | Board Of Trustees Of The University Of Arkansas | Drug-surfactant complexes for sustained release |
WO2007072503A2 (en) | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
US20070281016A1 (en) | 2006-06-06 | 2007-12-06 | Endo Pharmaceuticals Inc., A Delaware Corporation | Sustained release oxycodone composition with acrylic polymer and surfactant |
US20080014228A1 (en) | 2006-07-14 | 2008-01-17 | Olivia Darmuzey | Solid form |
AR073435A1 (es) | 2006-10-18 | 2010-11-10 | Senosiain S A De C V Lab | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine |
TR200708925A1 (tr) | 2007-12-26 | 2009-07-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları |
US20090214648A1 (en) * | 2008-02-15 | 2009-08-27 | Malathi Kandakatla | Pharmaceutical formulations comprising ibuprofen and diphenhydramine |
US7794750B2 (en) | 2008-06-20 | 2010-09-14 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
BRPI0923836A2 (pt) | 2008-12-31 | 2015-07-21 | Upsher Smith Lab Inc | Composições farmacêuticas orais contendo opióide e métodos |
EP2477610A1 (en) | 2009-09-17 | 2012-07-25 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
AU2011271429B2 (en) | 2010-06-30 | 2016-04-21 | Upsher-Smith Laboratories, Llc | Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid |
-
2009
- 2009-12-31 EP EP09795677A patent/EP2477610A1/en not_active Withdrawn
- 2009-12-31 AU AU2009352681A patent/AU2009352681B2/en not_active Ceased
- 2009-12-31 CA CA2773521A patent/CA2773521C/en not_active Expired - Fee Related
- 2009-12-31 WO PCT/US2009/069912 patent/WO2011034554A1/en active Application Filing
- 2009-12-31 BR BR112012008317A patent/BR112012008317A2/pt not_active IP Right Cessation
- 2009-12-31 US US13/496,818 patent/US9023390B2/en not_active Expired - Fee Related
-
2012
- 2012-03-09 CL CL2012000626A patent/CL2012000626A1/es unknown
-
2015
- 2015-04-28 US US14/697,891 patent/US9456985B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2477610A1 (en) | 2012-07-25 |
US20150238423A1 (en) | 2015-08-27 |
US9023390B2 (en) | 2015-05-05 |
AU2009352681A1 (en) | 2012-03-22 |
CL2012000626A1 (es) | 2013-02-08 |
US20120252833A1 (en) | 2012-10-04 |
CA2773521C (en) | 2017-01-24 |
US9456985B2 (en) | 2016-10-04 |
AU2009352681B2 (en) | 2014-11-20 |
CA2773521A1 (en) | 2011-03-24 |
WO2011034554A1 (en) | 2011-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012008317A2 (pt) | produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal | |
BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
DOP2010000387A (es) | Compuestos pirazolicos 436 | |
CL2008003284A1 (es) | Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. | |
AR088232A1 (es) | Composiciones farmaceuticas | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
CO6612204A2 (es) | Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
EA201170512A1 (ru) | Композиция для перорального введения | |
SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
MX2013008197A (es) | Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas. | |
UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
BRPI0909211B8 (pt) | formulação oral em forma de comprimido de compostos de tetraciclina | |
UY31839A (es) | Compuestos | |
GT201400042A (es) | Compuesto de benzotiazolona | |
ECSP13012832A (es) | Compuestos de pirazol como antagonistas de crth2 | |
CL2008002005A1 (es) | Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer. | |
CL2008003711A1 (es) | Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica. | |
BRPI0906045A2 (pt) | "composição farmacêutica para administração nasal" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |